Patents by Inventor HÉLÈNE SICARD

HÉLÈNE SICARD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20240425586
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Application
    Filed: June 3, 2024
    Publication date: December 26, 2024
    Inventors: CÉCILE BONNAFOUS, HÉLÈNE SICARD, RENAUD BUFFET, MATHIEU BLERY
  • TREATMENT WITH ANTI-KIR3DL2 AGENTS
    Publication number: 20240391999
    Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.
    Type: Application
    Filed: April 29, 2024
    Publication date: November 28, 2024
    Inventors: CARINE PATUREL, HELENE SICARD
  • Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
    Patent number: 12084498
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: September 10, 2024
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet
  • Treatment of peripheral T cell lymphoma
    Patent number: 11999784
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 4, 2024
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
  • Treatment with anti-KIR3DL2 agents
    Patent number: 11970535
    Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: April 30, 2024
    Assignee: INNATE PHARMA
    Inventors: Carine Paturel, Helene Sicard
  • KIR3DL2 BINDING AGENTS
    Publication number: 20240124579
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Application
    Filed: December 27, 2023
    Publication date: April 18, 2024
    Inventors: LAURENT GAUTHIER, SIMON KOLLNBERGER, BENJAMIN ROSSI, HÉLÈNE SICARD, CARINE PATUREL, STÉPHANIE CORNEN, STÉPHANIE ZERBIB
  • KIR3DL2 binding agents
    Patent number: 11858990
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: January 2, 2024
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Simon Kollnberger, Benjamin Rossi, Hélène Sicard, Carine Paturel, Stéphanie Cornen, Stéphanie Zerbib
  • COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20210363248
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Inventors: CÉCILE BONNAFOUS, HÉLÈNE SICARD, RENAUD BUFFET
  • Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
    Patent number: 11078275
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: August 3, 2021
    Assignee: INNATE PHARMA
    Inventors: Cecile Bonnafous, Helene Sicard, Renaud Buffet
  • TREATMENT WITH ANTI-KIR3DL2 AGENTS
    Publication number: 20210087270
    Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.
    Type: Application
    Filed: December 8, 2020
    Publication date: March 25, 2021
    Inventors: CARINE PATUREL, HELENE SICARD
  • KIR3DL2 BINDING AGENTS
    Publication number: 20200199228
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Inventors: LAURENT GAUTHIER, SIMON KOLLNBERGER, BENJAMIN ROSSI, HÉLÈNE SICARD, CARINE PATUREL, STÉPHANIE CORNEN, STÉPHANIE ZERBIB
  • KIR3DL2 binding agents
    Patent number: 10577419
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: March 3, 2020
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Simon Kollnberger, Benjamin Rossi, Hélène Sicard, Carine Paturel, Stéphanie Cornen, Stéphanie Zerbib
  • TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20190315857
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 17, 2019
    Inventors: CÉCILE BONNAFOUS, HÉLÈNE SICARD, RENAUD BUFFET, MATHIEU BLERY
  • TREATMENT WITH ANTI-KIR3DL2 AGENTS
    Publication number: 20190248895
    Abstract: This disclosure relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.
    Type: Application
    Filed: October 19, 2017
    Publication date: August 15, 2019
    Inventors: CARINE PATUREL, HELENE SICARD
  • Treatment of peripheral T cell lymphoma
    Patent number: 10344087
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: July 9, 2019
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
  • COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20190127463
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 2, 2019
    Inventors: CECILE BONNAFOUS, HELENE SICARD, RENAUD BUFFET
  • KIR3DL2 binding agents
    Patent number: 10246510
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: April 2, 2019
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Benjamin Rossi, Hélène Sicard, Carine Paturel
  • Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
    Patent number: 10174112
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 8, 2019
    Assignee: INNATE PHARMA
    Inventors: Cecile Bonnafous, Helene Sicard, Renaud Buffet
  • COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20170298132
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 19, 2017
    Inventors: CECILE BONNAFOUS, HELENE SICARD, RENAUD BUFFET
  • A COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20160002345
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnostic of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The disclosure also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Application
    Filed: February 20, 2014
    Publication date: January 7, 2016
    Inventors: CÉCILE BONNAFOUS, HÉLÈNE SICARD, RENAUD BUFFET